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Abstract
Introduction: Dopamine (DA) binds to five receptors (DAR), classified by their ability to increase (D1R-like) or decrease (D2R-
like) cAMP. In humans, most DA circulates as dopamine sulfate (DA-S), which can be de-conjugated to bioactive DA by
arylsulfatase A (ARSA). The objective was to examine expression of DAR and ARSA in human adipose tissue and determine
whether DA regulates prolactin (PRL) and adipokine expression and release.
Methods: DAR were analyzed by RT-PCR and Western blotting in explants, primary adipocytes and two human adipocyte
cell lines, LS14 and SW872. ARSA expression and activity were determined by qPCR and enzymatic assay. PRL expression and
release were determined by luciferase reporter and Nb2 bioassay. Analysis of cAMP, cGMP, leptin, adiponectin and
interleukin 6 (IL-6) was done by ELISA. Activation of MAPK and PI3 kinase/Akt was determined by Western blotting.
Results: DAR are variably expressed at the mRNA and protein levels in adipose tissue and adipocytes during adipogenesis.
ARSA activity in adipocyte increases after differentiation. DA at nM concentrations suppresses cAMP, stimulates cGMP, and
activates MAPK in adipocytes. Acting via D2R-like receptors, DA and DA-S inhibit PRL gene expression and release. Acting
via D1R/D5R receptors, DA suppresses leptin and stimulates adiponectin and IL-6 release.
Conclusions: This is the first report that human adipocytes express functional DAR and ARSA, suggesting a regulatory role
for peripheral DA in adipose functions. We speculate that the propensity of some DAR-activating antipsychotics to increase
weight and alter metabolic homeostasis is due, in part, to their direct action on adipose tissue.
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Introduction
Catecholamines (CA) are synthesized from tyrosine by a
sequential enzymatic conversion of dopamine (DA) to norepi-
nephrine (NE) and epinephrine (EPI). DA binds to five G-protein-
coupled, seven transmembrane domain receptors (DAR), classified
as those that are linked to stimulation (D1R and D5R) or
inhibition (D2R, D3R and D4R) of adenylate cyclase (AC) [1,2].
When coupled to Gas proteins, D1-like receptors can activate the
protein kinase A (PKA), mitogen activated protein kinase (MAPK),
and cGMP/PKG pathways [3–6]. The D2-like receptors are
coupled to Gai/o proteins and inhibit AC, followed by the
suppression of cAMP [7]. DA is a pleiotropic compound that acts
as a neurotransmitter and a hormone. In the brain, DA rapidly
alters electrical activity, ion channels and neurotransmitter release.
In peripheral non-neuronal tissues, e.g., pituitary, kidney and
blood vessels, DA acts more slowly and affects electrolyte
transport, vasodilation, hormone production and cell proliferation
[7,8].
DA is the primary inhibitor of pituitary prolactin (PRL)
release [9]. Unique to humans, PRL is also produced in multiple
extrapituitary sites, where it functions as a cytokine [10]. After
discovering de novo synthesis of PRL in human adipose tissue
[11,12], we examined its regulation. When adipocytes were
placed in culture, PRL release increased for several days [13].
This resembled the progressive rise in PRL release from
cultured pituitary cells, which is attributable to the removal of
tonic inhibition by hypothalamic DA [14]. We initially ruled out
DA as the inhibitor of adipose PRL because a ready source of
DA to the adipocytes was not apparent, and there was no
information on DAR expression in human adipose tissue, except
for a single report describing a novel DAR in rat brown adipose
tissue [15].
Dopamine sulfate (DA-S) is the major form of circulating DA in
humans [16,17]. Sulfoconjugation is carried out in the gastroin-
testinal (GI) tract by SULT1A3 sulfotransferase [16,18]. Basal
serum DA-S levels at <10 nM exceeds by 5 fold the combined
levels of free DA (1.5 nM), NE (1 nM) or Epi (0.2 nM). The
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compared to several minutes for unmodified DA [19]. However,
unlike inactivation of DA by deamination, O-methylation or
glucuronidation, sulfoconjugation is reversible, and DA-S can be
converted back to bioactive DA by arylsulfatase A (ARSA), a
releasable lysosomal enzyme [20,21]. We reasoned that if
adipocytes express DAR and possess an active ARSA, circulating
DA-S can serve as an inhibitor of adipose PRL.
Production of adipokines is a major function of adipose tissue.
Leptin is an important adipokine which is involved in body
weight regulation via its effects on food intake and energy
expenditure [22]. Adiponectin is a key adipose-derived hormone
which plays critical roles in fuel homeostasis, insulin action and
atherosclerosis [23]. Interleukin-6 (IL-6) is an inflammatory
cytokine which is produced by both macrophages and
adipocytes and whose release is increased in obesity [24]. The
production/release of these adipokines is differentially regulated
in human adipocytes by beta adrenergic receptor (b-AR)
agonists [25–28]. DA was recently reported to suppress leptin
expression and release in 3T3-L1 murine adipocytes [29], but
there is no information on comparable effects of DA on human
adipocytes.
The objective of this study was to detect expression of DAR in
human adipocytes at both the mRNA and protein levels and
confirm their functionality by examining the effects of DA on
PRL, leptin, adiponectin and IL-6 release. To this end, we
undertook a comprehensive approach and used adipose tissue
explants, primary adipocytes and two human adipocyte cell lines:
LS14 which we have cloned from a metastatic liposarcoma [30],
and SW872, a liposarcoma-derived cell line obtained from the
ATCC. Both cell lines differ with respect to gene expression and
the timing of full differentiation.
Materials and Methods
Ethics Statement
Written informed consents, approved by the Institutional
Review Board of the Christ Hospital of Cincinnati, were obtained
from all participants.
Patients, explant preparation and cell harvesting
Subcutaneous (sc) adipose tissue was obtained from non-obese,
non-diabetic women (BMI,30) undergoing elective abdomino-
plasty. Adipose explants were placed in 48-well plates (80–
100 mg/well) containing DMEM:F12 with 1% ITS
+ (BD
Biosciences, San Jose, CA) and incubated with the various
treatments. For cell harvesting, tissue fragments were digested
with collagenase as described [13]. After filtration and brief
centrifugation, the floating mature adipocytes (100 ml of packed
cells) were incubated in collagen-coated plates containing
DMEM:F12 with 1% ITS
+ and the various treatments. The
stromal vascular cell (SVC) fraction which contains the preadipo-
cytes was sedimented, and after treatment with erythrocyte lysis
buffer, cells were cultured in DMEM:F12 with 10% FBS and
50 mg/ml Primocin (Invitrogen, San Diego, CA). After 2–3
passages, cells were frozen until used.
Cell culture and differentiation
LS14 cells were cultured as described [13], while SW872 cells
were maintained in DMEM:F12 with 10% FBS. For differenti-
ation, primary sc preadipocytes, SW872 and LS14 cells were
plated in collagen-coated 24 well plates at 100,000 cells/well. Cells
were incubated in serum-free basal adipogenesis medium (BAM)
as described [13]. Adipogenesis was induced by the addition of
250 mM IBMX (BioMol, Plymouth Meeting, PA). After three
days, cells were incubated in BAM without IBMX, and cell
differentiation was monitored visually. On days 10–14, 80–90% of
either primary or cell lines, showed lipid accumulation. After
overnight incubation in DMEM/F12 plus 1% CSS, cells were
treated as described below.
Generation of stably transfected SW872 cells and
luciferase assay
The full-length superdistal PRL promoter (dPRL) cloned into
the PGL3E luciferase reporter vector (Promega, San Louis
Obispo, CA) was provided by Dr. Brar, Children’s Hospital,
Cincinnati, OH. SW872 cells were co-transfected with dsRed2-N1
plasmid (Clontech, Mountain View, CA) and the dPRL/PGL3E
construct at a 1:10 ratio using Fugene 6 (Roche, Indianapolis, IN).
After 72 hr, cells were selected using 0.8 mg/ml G418 (Sigma, St
Louis, MO). Colonies were picked, expanded and the cells were
maintained thereafter in 0.08 mg/ml G418. The stably transfected
cells were induced to differentiate, serum starved, and treated as
indicated below. After lysing with Passive Lysis Buffer (Promega),
luciferase activity was determined using Microplate Luminometer
(Dynex Technologies, Chantilly, VA).
Conventional and Real-time RT-PCR
RNA isolation and cDNA synthesis were done as described
[13]. Conventional PCR was performed using intron-spanning
primers (Table 1). For D1R/D5R which have no introns, DNAse
was added during RNA isolation. Additionally, samples were
evaluated for genomic DNA contamination using no reverse
transcriptase control. Cycle conditions were: 96 C for 6 min for
polymerase activation, followed by 35 cycles of 94, 57, and 72 C,
each for 45 sec. Products were resolved on a 1.5% agarose gel
containing ethidium bromide and photographed. Quantitative
real-time PCR (qPCR) was performed with SYBR Green and the
appropriate primers (Table 1). Fluorometric products were
detected with Applied Biosystem StepOnePlus instrument. Cycle
parameters were: 96 C for 6 min, followed by 45 cycles of 94 C for
15 sec, 57 C for 15 sec, and 72 C for 30 sec, and an optical read at
83.5 C for 6 sec. Product purity was confirmed by DNA melting
curve analysis and agarose gel electrophoresis. PCR efficiency was
determined using the LinRegPCR program or by cDNA dose
response curve analysis. b2-Microglobulin (B2M) was used as a
reference gene. Fold changes in gene expression were calculated
from cycle threshold and efficiency measurements as described
[13].
PRL release studies
Adipose tissue explants, mature adipocytes or differentiated
primary adipocytes, LS14 and SW872 cells were incubated with
DA, bromocriptine (a D2R agonist), isoproterenol (all from
Sigma), dopamine-4-O-sulfate (from NIMH) or raclopride, a
D2R antagonist (Tocris, Ellisvile, MO). After 24 h, conditioned
media (CM) were collected and aliquots were analyzed for PRL by
the Nb2 bioassay, which is approximately 50 times more sensitive
than RIA or ELISA for PRL [13]. Briefly, rat Nb2 lymphocytes
were serum-starved and plated in 96-well plates at 30,000 cells/
well. Cells were incubated with recombinant human PRL (Protein
Laboratories, Rehovot, Israel) in triplicate or with CM aliquots in
duplicate. After 72 h, cell viability was determined by fluorescence
using resazurin reduction. PRL concentration in CM was
calculated from a standard curve, with the lowest detectable level
of 2 pg/well. Nb2 cell proliferation was not affected by the tested
compounds.
Dopamine Receptors in Human Adipocytes
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Gene
Genbank Accession
Number Forward primer (59R39) Reverse Primer (59R39)
Amplimer
Size (bp)
B2M NM_004048 GGCATTCCTGAAGCTGAC GAATCTTTGGAGTACGCTGG 114
ARSA NM_000487 TATGCCTCTCACCACAC GGTCTCAGGTCCATTGTC 191
ARSB NM_000046 GCTACCAGATCCGTACAG TTCCGGTACATTCCCAG 153
ARSC NM_000351 AGCACTGATAGGGAAATGG AGCAAGGGTAAGGAGGG 216
DRD1 NM_000794 CTCCGTTTCCAAATACATTCCA CACTGTTGATTCTTTGCCCT 169
DRD2 NM_000795 AGCATCGACAGGTACACAG CTCGTTCTGGTCTGCGT 159
DRD3 NM_033660 GTGGTATACCTGGAGGTGAC GCAGTGTACCTGTCTATGCT 136
DRD4 NM_000797 CCGCTCTTCGTCTACTC ACAGGTTGAAGATGGAGG 114
DRD5 NM_000798 CTCATCTCCTACAACCAAGAC TGATAGATCTGGAACATGCGA 148
PRL NM_000948 TTCAGCGAATTCGATAAACGG TGATACAGAGGCTCATTCCAG 181
PRLR NM_000949 CGTGACTTACATAGTTCAGCCA GGAGCGTGAACCAACCA 139
All primer sets were intron-spanning except those for D1 and D5 dopamine receptors. B2M-b2 microglobulin, ARSA-arylsulfatase A, ARSB-arylsulfatase B, ARSC-
arylsulfatase C (steroylsulfatase), DRD1-D1 dopamine receptor, DRD2-D2 dopamine receptor, DRD3-D3 dopamine receptor, DRD4-D4 dopamine receptor, DRD5-D5
dopamine receptor, PRL-prolactin, PRLR-prolactin receptor.
doi:10.1371/journal.pone.0025537.t001
Figure 1. DAR expression in human adipose tissue and adipocytes. A, comparison of DAR expression in human pituitary (P), striatum (S) and
sc adipose tissue (A), as determined by conventional RT-PCR. B, expression of selected DAR in the stromo-vascular cell (SVC) fraction and mature
adipocytes, as determined by real-time PCR. Data are expressed as relative changes over SVC. Each value is a mean6SEM of 3 determinations; *,
p,0.05. C, Immunoblot of selected DAR proteins in tissues and cells. Lanes: 1, pituitary; 2, proliferating primary preadipocytes; 3, proliferating LS14; 4,
proliferating SW872; 5, differentiated primary adipocytes; 6, differentiated LS14; 7, differentiated SW872. Each lane was loaded with 40 mg proteins,
except for the pituitary (30 mg proteins). b-actin (b-Act) was used as a loading control. Expression of D1R, D2R and D4R (panel D), and PRL vs PRLR
(panel E) during adipogenesis in LS14 cells was determined by qPCR. Data are expressed as relative changes over day 0, and were calculated from
the cycle threshold and efficiency measurements (Mean6SEM of 3 determinations).
doi:10.1371/journal.pone.0025537.g001
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Cells were homogenized in lysis buffer and 35 mg of lysate
proteins were separated on 12% SDS gels and transferred to
nitrocellulose membranes. For DAR, validated antibodies [31–33]
against D1R (Calbiochem, San Diego, CA: 324390; 1:2,000), D2R
(Santa Cruz, CA: SC-5303; 1:250), and D4R (Calbiochem:
324405; 1:1000) were used. For signaling pathways, ERK1/2
(ab #9102) phospho ERK 1/2 (Thr202/Tyr204 ab #9101S),
Phospho Akt (Ser473, ab #9271S) and Akt (ab #9272), all from
Cell signaling (Danvers, MA) were used at 1:1000. After
incubation with horseradish peroxidase-conjugated secondary
antibodies, products were exposed to SuperSignal chemilumines-
cence reagents (Pierce, Rockford, IL) and photographed; b-actin
(Sigma, A1978;1:5000) was used as a loading control.
Arylsulfatase A Activity
ARSA activity was determined by the method of Chang et al
[34] after modifications. Briefly, samples were homogenized in
0.05 M acetate buffer, pH 5.0, freeze-thawed, and centrifuged at
12,0006g for 5 min. Lysates (15 mg) or CM (X10 concentrated)
were incubated at 37C in 0.05 M acetate buffer, pH 5.6
containing 3 mM lead acetate, and 5 mM 4-methylumbelliferyl
sulfate (Sigma), with or without 3 mM Ag+. After 30 min, the
reaction was stopped with 0.2 M glycine-carbonate buffer,
pH 10.4 and 1 mM EDTA. Fluorescence was measured at
370 nm excitation and 450 nm emission, using Gemini fluorescent
microplate reader (Molecular Devices, Sunnyvale, CA). Enzyme
activity was calculated from a standard curve.
cAMP and cGMP determinations
Cells were incubated with the various treatments for 30 min
and then lysed in 0.1 M HCl. After centrifugation, the supernatant
was analyzed for cAMP and cGMP using respective ELISA kits
from Cayman Chemical Co (Ann Arbor, MI). To increase assay
sensitivity for cGMP analysis, samples were first acetylated
according to manufacturer’s instructions.
Adipokine determination
Fluorescent sandwich ELISAs for human leptin, adiponectin
and IL-6 were optimized in our lab as described [35]. Briefly,
matched monoclonal ab pairs against leptin (R&D Systems,
Minneapolis MN; MAB398 for capture and BAM398 for
detection), adiponectin (R&D systems; MAB10651 for capture
and BAM1065 for detection) and IL-6 (Invitrogen, Carlsbad CA;
AHC0562 for capture and AHC0469 for detection) were used.
Plates coated with the capture ab were co-incubated with
biotinylated detection ab, antigen standards and CM from
explants or cells. Streptavidin-conjugated horseradish peroxidase
was added, followed by a fluorimetric substrate (QuantaBlue;
Thermo-Fisher, Rockford, IL). Plates were read at 325 nm
excitation and 420 nm emission.
Data Analysis
Experiments were repeated at least 3 times. Values were
expressed as means6SEM. Data were analyzed by Student’s t test
or ANOVA. P,0.05 was considered significant.
Results
Expression of DAR in adipose tissue and adipocytes
Conventional RT-PCR was used to compare the expression of
DAR in sc adipose tissue, striatum and pituitary. Four of the five
DAR were detected in adipose tissue, with D1R being the most
abundant (Fig. 1A). As expected, the pituitary showed high
expression of D2R, D4R and D5R, while the striatum showed
differential expression of all DAR. As determined by qPCR, the
relative expression of D1R is higher, while that of D2R is lower in
mature adipocytes than the SVC fraction, while expression of
D4R was similar in the two fractions (Fig. 1B).
Figure 2. Expression of active arylsulfatase A (ARSA) in adipose tissue and adipocytes and confirmation of DA-S bioactivity. A,
comparison of mRNA levels of ARSA (A), ARSB (B) and ARSC (C) in sc adipose tissue, as determine by qPCR. Data are expressed as fold changes in gene
expression over ARSB, and were calculated from the cycle threshold and efficiency measurements. B, ARSA activity before (light bars) and after (dark
bars) differentiation of LS14 and SW872 adipocytes. Specific ARSA activity was determined by subtracting enzyme activity in the presence of silver
nitrate from total enzyme activity. Each value is a mean6SEM of 4 determinations; *, p,0.05. C, both DA and DA-S inhibit PRL release from sc adipose
tissue explants, whereas isoproterenol (ISO), a b-AR agonist, causes stimulation. Explants were incubated with the different compounds for 24 hr and
PRL concentration in CM was determined by the Nb2 bioassay. Data are expressed as % of control. Each value is a mean6SEM of 6 determinations;
*, p,0.05.
doi:10.1371/journal.pone.0025537.g002
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proteins in primary adipocytes, LS14 and SW872 cells before and
after differentiation. Fig. 1C shows that D1R, D2R and D4R
proteins were expressed at variable amounts in the pituitary
(serving as a positive control), and in the three types of adipocytes.
There was an apparent downregulation of D1R and D4R, but
upregulation of D2R, in LS14 cells after differentiation. All
receptors examined showed some evidence of isoforms.
Changes in D1R, D2R and D4R mRNA levels during
adipogenesis in LS14 cells were determined by qPCR. Fig. 1D
shows a reduction in D1R, but an increase in D2R, during the first
three days of differentiation. Expression of D4R was reduced on
day 3 and remained suppressed until day 10. PRL expression was
increased during the first six days of differentiation, followed by a
decline, whereas PRLR expression showed a significant reduction
throughout adipogenesis (Fig. 1D).
Adipocytes express an active ARSA and respond to DA-S
We used qPCR to compare the expression of arylsulfatase A
(ARSA), specific for catecholamines and cerebrosides, arylsulfatase
B (ARSB), specific for glycosaminoglycans, and arylsulfatase C
(ARSC), specific for steroids [21]. The mRNA levels of ARSA and
ARSC in sc adipose tissue were 4.5 and 2.5 fold higher,
respectively, than those of ARSB (Fig. 2A). An enzymatic assay
that measures total arylsulfatase activity was then employed. In the
presence of silver nitrate, only ARSA activity is blocked, enabling
the calculation of its activity by subtraction from total enzyme
activity. As shown in Fig. 2B, basal ARSA activity was detectable
in non-differentiated LS14 and SW872 cells, increasing 8 and 20
fold, respectively, after differentiation. ARSA activity was also
detectable in CM from differentiated adipocytes (data not shown).
To determine whether adipocytes can convert DA-S to bioactive
DA, the effects of DA and DA-S on PRL release from sc adipose
explants were compared. Fig. 2C shows a similar inhibition of
PRL release by both DA and DA-S. The b-AR agonist
isoproterenol (ISO), stimulated PRL release, showing an inverted
U-shaped dose-dependent curve.
PRL release from all types of adipocytes is inhibited by
both DA and bromocriptine
We next examined whether DA directly affects PRL release by
the adipocytes. Fig. 3 shows a similar DA-induced inhibition of
PRL release from mature adipocytes (panel A), differentiated
primary preadipocytes (panel B), differentiated LS14 cells (panel
C), and differentiated SW872 cells (panel D). Bromocriptine
(BRO), a specific D2R agonist, mimicked the inhibitory effect of
DA. A non-monotonic dose-dependent inhibition of PRL release
was apparent in all cases, with 1 and 10 nM, but not 100 nM, of
DA and BRO showing effective inhibition.
Both DA and DA-S suppress PRL gene expression via the
superdistal promoter
A diagram of the proximal and superdistal promoters that
regulate pituitary and extrapituitary PRL, respectively, is shown in
Fig. 4A. The superdistal promoter is located 5.8 kB upstream of
the pituitary start site [10], and contains putative CREB (cAMP
response element binding protein) and c/EBP (CCAAT/enhancer
binding protein) transcription binding sites in the proximal region,
as well as two AP-1 sites in the more distal region (Fig. 4B).
SW872 cells, stably transfected with a luciferase reporter driven by
the 3000 kb superdistal promoter (Fig. 4B), were used. Within
6 hr, as little as 0.1 nM of DA or DA-S suppressed PRL
expression (Fig. 4C), an effect that was also seen after 24 hr
(Fig. 4D). As was the case with PRL release (Fig. 3), a non-linear,
dose-dependent curve was evident, suggesting activation of
stimulatory DAR at the higher DA-S/DA doses. IBMX, a
phosphodiesterase inhibitor, increased PRL expression 4 fold,
supporting the role of the cAMP system in the transcriptional
control of adipocyte PRL.
DAR signal through multiple pathways in the adipocytes
To further characterize the DAR that mediates the suppression
of PRL by DA, adipose explants (Fig. 5A) and differentiated
SW872 cells (Fig. 5B) were pretreated with 100 nM raclopride, a
selective D2R antagonist, before incubation with 10 nM DA for
24 hrs. In both cases, raclopride abrogated the inhibitory action of
DA on PRL release, indicating mediation by D2R. The ability of
DA to affect intracellular cAMP and cGMP concentrations in
LS14 cells was then examined. Within 30 min of incubation, 1 and
10 nM DA suppressed, while 100 nM DA had no effect, on
intracellular cAMP levels (Fig. 5C). On the other hand, DA at
Figure 3. DA and bromocriptine (BRO) inhibit PRL release from
different types of adipocytes. A, isolated sc mature adipocytes. B,
differentiated sc primary adipocytes. C, differentiated LS14 cells. D,
differentiated SW872 cells. In each case, cells were incubated with
different doses of DA or bromocriptine (BRO) for 24 hr, and PRL in CM
was determined by the Nb2 bioassay. Each value is a mean6SEM of 6
determinations; *, p,0.05.
doi:10.1371/journal.pone.0025537.g003
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within 30 min of incubation (Fig. 5D); a stimulatory effect on
cGMP was also obtained in response to 10 nM ISO (data not
shown).
Western blotting was then used to examine the effects of DA on
the MAPK and PI3K pathways. As show in Fig. 5E, within 5 min
of incubating differentiated LS14 cells with 10 nM DA, ERK1/2
phosphorylation increased, remained elevated for another 10 min,
and reduced to basal levels by 120 min. Akt phosphorylation was
suppressed at 15 min, and was unchanged or slightly stimulated
thereafter.
DA differentially affect the release of selected adipokines
The effects of low (1 nM) and high (100 nM) doses of DA on
leptin release were examined using sc adipose explants (Fig. 6A),
isolated mature adipocytes (Fig. 6B), and differentiated primary
adipocytes (Fig. 6C). Within 24 hr of incubation, leptin release
was inhibited by 40–80% by either dose of DA. The potent D1R/
D5R antagonist, SKF38393 at 10 nM, mimicked the inhibitory
effect of DA, suggesting an action via D1R-like receptor while not
excluding involvement of other receptors. Within 24 hr of
incubation, both DA and SKF caused 60–80% stimulation of
adiponectin release from differentiated primary adipocytes
(Fig. 6D). Incubation of proliferating primary adipocytes for
6 hr with 1 nM DA or 10 nM SKF resulted in a moderate, 30–
40% stimulation of IL-6 release (Fig. 6E).
Discussion
This is the first report on expression of functional DAR in human
adipose tissue and adipocytes. Our data suggest that D2R mediate
the inhibitory effect of DA on adipocyte PRL gene expression and
release,whereasD1R-like receptorsareinvolvedintheregulationof
adipokine/cytokine release. A second important finding is that
human adipose tissue and adipocytes express an active ARSA,
capable of de-conjugating DA-S to bioactive DA. Collectively, these
findings underscore a novel role for the peripheral dopaminergic
system in the regulation of adipose tissue functions, with many
implications to metabolic homeostasis in health and disease. For
example, we propose that the ability of widely-prescribed
antipsychotic medications, most of which act by binding to various
DAR, to cause weightgainand alter metabolic homeostasis [34,36],
could be due, in part, to their direct action on adipose tissue.
The D1-like and D2-like receptors differ in sequence, ligand
binding, coupling to Gs and Gi proteins, and signaling pathways
Figure 4. Both DA and DA-S suppress adipocyte PRL gene expression via the superdistal promoter. A, diagram of the pituitary and
superdistal promoters which regulate pituitary and extrapituitary PRL expression, respectively; both generate an identical PRL protein. UTR,
untranslated region; SP, signal peptide. B, the superdistal PRL promoter construct driving a luciferase reporter that was stably transfected in SW872
cells. Also shown are putative transcription factor binding sites capable of responding to activation of PKA and MAPK signaling. C, inhibition of PRL
gene expression by DA and DA-S after 6 hr of incubation; D, inhibition of PRL gene expression by DA and stimulation by IBMX after 24 hrs of
incubation. Stably transfected SW872 cells were induced to differentiate and then incubated with increasing doses of DA or DA-S (0.1 nM to 100 nM)
or with 250 mM IBMX. Luciferase activity was determined in cell lysates by luminommetry. Each value is a mean6SEM of 6 determinations; *, p,0.05.
doi:10.1371/journal.pone.0025537.g004
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their brain counterparts due to coupling to various effectors. Given
the 80% sequence homology of D1R and D5R, they lack
discriminating agonists and antagonists. Our Western blots
showed evidence for several DAR isoforms in adipocytes, the
ratio of which was altered following differentiation. Upon probing
with an ab against D5R, multiple bands were seen (data not
shown), which could be due either to D5R isoforms or to non-
specificity of the ab. The difference in DAR expression between
the SVC fraction and mature adipocytes (Fig. 1B) could be due to
DAR expression by resident cells such as lymphocytes [37,38] and
endothelial cells [31] and should be further examined.
Both Western blotting and qPCR showed dissimilar changes in
D1R and D2R expression during adipogenesis, with the most
notable changes occurring during the first three days. Using the
Genomatix MatInspector program, we identified several putative
binding sites or transcription factors in the promoters of D1R and
D2R. As illustrated in Fig. 7, both receptors have CREB and AP-
Figure 5. Different signaling pathways mediate DAR actions in the adipocytes. Sc adipose explants (panel A), or differentiated SW872 cells
(panel B) were incubated with 10 nM DA or 100 nM raclopride (RAC), a D2R antagonist, for 24 hr, or pre-incubated with RAC 1 hr before DA
addition. PRL in CM was determined by the Nb2 bioassay. Each value is a mean6SEM of 6 determinations; *, p,0.05. Differentiated LS14 cells were
incubated with 1, 10 or 100 nM DA for 30 min and intracellular cAMP (panel C) or cGMP (panel D) levels were determined by respective ELISAs.
Each value is a mean6SEM of 4 determinations; *, p,0.05. E, differentiated LS14 cells were incubated with 10 nM DA, and cell lysates obtained at
different times were analyzed for phosphorylate ERK1/2 (pERK1/2) and phosphorylated Akt (pAkt) by Western blotting. Total ERK1/2 and Akt served
as loading controls.
doi:10.1371/journal.pone.0025537.g005
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CREB and MAPK signaling. Notably, there is also a PPARc binding
site in both receptors, and a C/EBP binding site in D1R. The C/
EBPs and PPARc are sequentially expressed during early differen-
tiation and are critical for the induction and maintenance of
adipogenesis. The presence of their consensus binding sites in DAR
promoters raises the possibility that similar to b-AR [39,40], DAR are
transcriptionally regulated during early adipogenesis by these factors.
The large concentration of DA-S in human serum is commonly
overlooked because most of the methods for measuring CA do not
detect DA-S. Sulfoconjugation is the major form of CA
inactivation in human serum, while glucuronidation predominates
in rats [16,18]. In humans, a single amino acid substitution (Glu
146) in SULT1A3 sulfotransferase confers the enzyme with a
higher affinity for DA than NE or Epi [41]. No orthologue of
SULT1A3 has been found in rodents, suggesting a greater
importance of DA sulfoconjugation in humans than in rodents
[42].
Adipose tissue is rich in ARSC (steroid sulfatase) which de-
conjugates sulfated steroids [43]. Together with aromatase, ARSC
maintains high local estrogen levels in the breast, and has been
studied for its impact on breast cancer [21]. Our data are the first to
demonstrate activeARSAinhumanadipose tissue.Themarkedrise
in enzyme activity after differentiation (Fig. 2B) could be due to
increased enzyme expression, or an increase in co-factors such as
saposin B [44] during adipogenesis. In addition to sulfated CA,
ARSA uses galactosylceramide sulfate as a substrate. Inherited
ARSA deficiency causes metachromatic leukodystrophy, a rare
lysosomal storage disease whose manifestation ranges from lethality
to motor and cognition deficits [45,46]. Over 100 mutations in
ARSA are known [47], with some causing total loss of enzyme
activity while others resulting only in mild impairment in enzyme
efficacy. Future studies should examine if polymorphisms in ARSA
alter adipose tissue functions that are regulated by DA.
The control of extrapituitary PRL production is poorly
understood. Studies by us [48] and others [49] showed no effects
of DA on PRL release from human decidual explants. This was
interpreted as insensitivity of the superdistal PRL promoter to DA
rather than an absence of DAR in the decidua. The present data
show that similar to the pituitary, DA suppresses adipocyte PRL
gene expression and release via D2R. This likely occurs through
inhibition of cAMP, followed by the suppression of PKA activity.
Notably, DAshoweda non-monotonicdose dependentinhibitionof
PRL in all adipocytes (Figs. 3 and 4). This suggests that activation
of inhibitory DAR at the low DA doses is masked by activation of
stimulatory DAR at the higher doses. Whether this occurs via
increased cGMP and/or MAPK activation, remains to be
determined. As depicted in Fig. 4B, the superdistal PRL promoter
has several cAMP responsive elements such as CREB, and C/EBP,
and two AP-1 sites which can respond to MAPK activation.
Figure 6. Effects of DA on adipokine/cytokine release. Sc explants (panel A), isolated mature adipocytes (Panel B) or differentiated primary
adipocytes (panel C) were incubated with 1 or 100 nM DA or with 10 nM of SKF38393, a D1R/D5R agonist, for 24 hr. Leptin concentration in CM was
determined by ELISA. Each value is a mean6SEM of 5 determinations; *, p,0.05. D, differentiated primary adipocytes were incubated as above and
adiponectin release was determined by ELISA. E, proliferating primary adipocytes were incubated with 1 or 100 nM DA or with 10 nM of SKF for 6 hr
and IL-6 release was determined by ELISA.
doi:10.1371/journal.pone.0025537.g006
Figure 7. Putative transcription factor binding sites in the
promoters of D1R and D2R. Sites were identified using Genomatix
MatInspector. The diagram is not drawn to scale.
doi:10.1371/journal.pone.0025537.g007
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stimulating of adipogenesis, inhibition of lipolysis and variable
effects on adipokine release (reviewed in [12]). Using visceral and
sc explants from 50 patients, we found attenuated PRL release
from sc explants from obese, but not in non-obese individuals [13].
Whether obesity is associated with alterations in ARSA activity,
DAR expression, and/or changes in the signaling pathways that
are activated by DA, is an intriguing issue which deserves further
exploration. Notably, expression of PRL and PRLR showed an
opposite pattern during early differentiation, followed by some
recovery of the PRLR but a fall for PRL (Fig. 1E). Additional
studies should examine the various factors that regulate expression
of the above genes during adipogenesis.
Adipose tissue produces numerous adipokines and cytokines
which participate in metabolic homeostasis and their dysregulation
affects food consumption, body weight, lipid metabolism and
inflammation [50,51]. Whereas the release of leptin was strongly
inhibited by DA, adiponectin and IL-6 were moderately
stimulated, suggesting differential effects of the dopaminergic
system on three important adipokines/cytokines. The ability of
SKF, a D1R/D5R agonist, to mimic the actions of DA on
adipokine release suggests involvement of D1R-like receptors. At
present, neither of our human adipocyte cell line produces
sufficient amounts of leptin or adiponectin to enable an in-depth
mechanistic studies. As was recently reported for increased
expression of leptin in 3T3-L1 adipocytes [52], we are exper-
imenting with different culture conditions of LS14 and/or SW872
cells to resolve this issue. Our attempts to verify the role of MAPK
in mediating the effects of DA on adipokine release were
complicated by the fact that incubation of adipose explants or
mature adipocytes with 5 mM U0126, a specific MEK inhibitor,
markedly suppressed leptin release (data not shown). This
suggested that another system(s), which is sensitive to MAPK
inhibition, is involved in leptin release.
Fig. 8 shows our proposed model on the involvement of the
peripheral dopaminergic system in adipose tissue functions. Both
DA-S and DA can reach the adipocytes via the circulation, from
infiltrating lymphocytes/macrophages, and from local sympathetic
nerve endings. Lysosomal ARSA is secreted into the adjacent
extracellular space where it can de-conjugate DA-S, enabling
binding of free DA to its receptors. It is unlikely that adipocytes
convert DA to NE, as this requires not only DA internalization,
but also expression of dopamine beta hydroxylase, which is
presumably specific to secretory granules within neurons and
adrenal chromaffin cells [1]. Activation of D2R by DA inhibits AC
and suppresses intracellular cAMP. This leads to inactivation of
PKA/CREB-responsive elements within the superdistal promoter
that regulates PRL gene expression, followed by a reduction in
PRL release. The actions of DA on leptin, adiponectin and IL-6
release are mediated by D1R-like receptors via signaling pathways
that may include PKA, PKG, or MAPK. Our model also assume
that b-AR, which are abundantly expressed in adipocytes [53]
contribute, in an unclear manner, to adipokine/cytokine release.
Finally, dopaminergic altering drugs are prescribed to millions
of patients with neuro-psychiatric disorders [54,55]. Many of these
drugs cause excessive weight gain, alter metabolic homeostasis and
increase the risk of death from cardiovascular disease [56]. These
effects have been solely attributed to the action of these drugs
within the brain. The data reported here should inspire the
reassessment of undesirable side effects of antipsychotics, by
considering their ability to directly affect adipocyte functions that
can lead to weight gain or changes in lipid metabolism and
circulating adipokines.
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